PHARVARIS NV

$15.80 0.00% ($0.00)
  • 1D
  • 1W
  • 1M
  • 1Y
  • 5Y
  • YTD

Get ready to invest

Subscribe

About PHARVARIS NV

Pharvaris B.V. operates as a clinical-stage company. The Company focuses on the discovery and development of novel oral B2-receptor antagonists for the treatment of patients. Pharvaris serves customers in the Netherlands and Switzerland.

Stock Analysis

last close $15.8
1-mo return -9.4%
3-mo return 9.3%
avg daily vol. 7.47T
52-week high 42.86
52-week low 13.14
market cap. $512M
forward pe -
annual div. -
roe -43.2%
ltg forecast 8.1%
dividend yield -
annual rev. $--
inst own. 81.5%
baraka

Subscribe now for daily local and international financial news

Subscribe